NCT05329779View on ClinicalTrials.gov

Study on Allopregnanolone and Depression in Perimenopausal Women

PHASE4RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

April 1, 2026

Study Completion Date

May 1, 2026

Conditions
Depression
Interventions
DRUG

brexanolone

Brexanolone is a derivative of allopregnanolone, which is FDA-approved to treat postpartum depression.

DRUG

placebo

The placebo is a 0.45% sodium chloride infusion.

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER